Chemoimmunotherapy Ups Survival in Triple-Negative Breast Cancer

Share this content:
Chemoimmunotherapy Ups Survival in Triple-Negative Breast Cancer
Chemoimmunotherapy Ups Survival in Triple-Negative Breast Cancer

MONDAY, Oct. 22, 2018 (HealthDay News) -- For patients with metastatic triple-negative breast cancer, atezolizumab plus nanoparticle albumin-bound (nab)-paclitaxel prolongs progression-free survival compared with placebo plus nab-paclitaxel, according to a study published online Oct. 20 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the European Society for Medical Oncology, held from Oct. 19 to 23 in Munich.

Peter Schmid, M.D., Ph.D., from the Queen Mary University of London, and colleagues randomly assigned patients with untreated metastatic triple-negative breast cancer to receive either atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel in a 1:1 ratio (451 patients in each group). Patients continued the intervention until disease progression or an unacceptable level of toxic effects.

The researchers found a median progression-free survival of 7.2 and 5.5 months with atezolizumab plus nab-paclitaxel and placebo plus nab-paclitaxel, respectively (hazard ratio [HR] for progression or death, 0.80; 95 percent confidence interval [CI], 0.69 to 0.92; P = 0.002) in the intention-to-treat analysis. The median progression-free survival was 7.5 and 5.0 months, respectively, among patients with programmed death ligand 1 (PD-L1)-positive tumors (HR, 0.62; 95 percent CI, 0.49 to 0.78; P < 0.001). Median overall survival was 21.3 and 17.6 months, respectively, in the intention-to-treat analysis (HR for death, 0.84; 95 percent CI, 0.69 to 1.02; P = 0.08) and 25.0 and 15.5 months, respectively, among patients with PD-L1-positive tumors (HR, 0.62; 95 percent CI, 0.45 to 0.86).

"It remains to be determined whether these findings extend to other chemoimmunotherapy combinations," the authors write.

The trial was funded by F. Hoffmann-La Roche/Genentech, which manufactures atezolizumab.

Abstract/Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Head Says Feds May Intervene to Cut Vaccine Exemptions

FDA Head Says Feds May Intervene to Cut ...

If states do not change lax vaccine laws, federal authorities may be forced to take action

New Kaiser Permanente Medical School Plans to Waive Tuition

New Kaiser Permanente Medical School Plans to Waive ...

School will waive all tuition for the full four years of school for its first five classes

Experimental Test May Quickly Diagnose Sepsis

Experimental Test May Quickly Diagnose Sepsis

Microelectrode device analyzes a patient's blood, provides results in as quickly as 2.5 minutes

is free, fast, and customized just for you!




Already a member?

Sign In Now »